Analysts have been eager to weigh in on the Healthcare sector with new ratings on PepGen Inc. (PEPG – Research Report), Viridian Therapeutics (VRDN – Research Report) and Blueprint Medicines (BPMC – Research Report).
PepGen Inc. (PEPG)
In a report issued on January 8, Joseph Schwartz from Leerink Partners reiterated a Buy rating on PepGen Inc.. The company’s shares closed last Wednesday at $7.27.
According to TipRanks.com, Schwartz is a 1-star analyst with an average return of
Currently, the analyst consensus on PepGen Inc. is a Strong Buy with an average price target of $23.00.
See Insiders’ Hot Stocks on TipRanks >>
Viridian Therapeutics (VRDN)
In a report issued on January 8, Thomas Smith from Leerink Partners maintained a Buy rating on Viridian Therapeutics. The company’s shares closed last Wednesday at $23.82.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Currently, the analyst consensus on Viridian Therapeutics is a Strong Buy with an average price target of $37.83.
Blueprint Medicines (BPMC)
In a report issued on January 9, Andrew Berens from Leerink Partners maintained a Sell rating on Blueprint Medicines. The company’s shares closed last Wednesday at $83.19.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $86.06 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PEPG:
